EQL Pharma AB (publ) (STO:EQL)

Sweden flag Sweden · Delayed Price · Currency is SEK
80.70
-1.20 (-1.47%)
At close: Jun 5, 2025
Market Cap 2.35B
Revenue (ttm) 373.52M
Net Income (ttm) 43.12M
Shares Out 29.06M
EPS (ttm) 1.44
PE Ratio 56.04
Forward PE 37.36
Dividend n/a
Ex-Dividend Date n/a
Volume 16,368
Average Volume 20,365
Open 82.10
Previous Close 81.90
Day's Range 79.40 - 83.00
52-Week Range 48.50 - 90.60
Beta 0.66
RSI 45.09
Earnings Date Jul 28, 2025

About EQL Pharma AB

EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden. [Read more]

Sector Healthcare
Founded 2006
Employees 21
Stock Exchange Nasdaq Stockholm
Ticker Symbol EQL
Full Company Profile

Financial Performance

In 2024, EQL Pharma AB's revenue was 373.52 million, an increase of 41.39% compared to the previous year's 264.17 million. Earnings were 43.12 million, an increase of 89.93%.

Financial Statements

News

There is no news available yet.